TruScreen Capital Raising

NZX and Media Release 22 March, 2017
TRUSCREEN ANNOUNCES CAPITAL RAISING
Capital investment to fund commercial opportunities.
Cervical cancer technology company, TruScreen Limited (NZAX:TRU) has undertaken a $4.09 million
share placement to institutional and other select investors as it looks to strengthen its balance sheet
and fund commercial growth. In addition to the placement, TruScreen intends to make an offer to
existing retail shareholders of the company, on the same terms and pricing, through a Share
Purchase Plan.
TruScreen, which has the world’s only certified, real time, objective primary screening device for
cervical cancer, has in recent times made significant advances to the design and performance of its
device, with the launch of its second generation TruScreen2 device in 2016. This has opened up
commercial opportunities in a number of international markets and TruScreen is in contention for a
number of large scale and government screening programs.
The Board wishes to raise new capital to strengthen the balance sheet, fund sales and marketing
initiatives, expand manufacturing capabilities and continue improvement to the devices
performance. In particular, funds will be used to:
 Prepare for anticipated commercial opportunities in China and India;
 Expand commercial growth in European and Latin American markets;
 Fund clinical and familiarisation trials as required for product improvement and acceptance
in government programs;
 Expansion of manufacturing facilities and supply capabilities;
 Build-up of inventory;
 Continued product refinement.

Chairman of TruScreen, Mr Robert Hunter, said: “Cervical cancer is a major cause of mortality
amongst women worldwide, particularly in countries that lack cervical cancer screening
programmes. We are now seeing increased investment from Governments into screening
programmes and are focused on positioning our real time, accurate and cost effective TruScreen2 as
the preferred technology for these large scale screening programmes. We have identified a number
of immediate opportunities and this capital raising will ensure we have the resources and capacity to
progress with these.
“We are delighted with the support we received for the placement from our large investors. The SPP
will allow our retail shareholders an equal opportunity to participate in this capital raising.”
Placement
The placement was undertaken with institutional and other select investors subscribing for
25,562,500 shares at 16c per share. Settlement and allotment of the new shares is expected to
occur on 24 March, 2017.

Share Purchase Plan
Existing retail shareholders of TruScreen will be invited to subscribe for new shares under a Share
Purchase Plan. The subscription price will be the same as that for the private placement, 16c per
share.
Key Dates
The record date for determining entitlements to participate in the Share Purchase Plan and other
key dates will be announced shortly.

ENDS
-ENDS-
For more information visit www.truscreen.com or contact Martin Dillon, TruScreen Chief Executive Officer,
email: martindillon@truscreen.com

About TruScreen:
TruScreen’s real time cervical cancer
technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the
surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between
normal and abnormal (cancerous and
precancerous) tissue to identify precancerous
change, or cervical intraepithelial neoplasia
(CIN). A Single Use Sensor (SUS) is used for
each patient to protect against cross-infection.